SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation
- 7 April 2005
- journal article
- Published by Elsevier BV in Biologicals
- Vol. 33 (2), 95-99
- https://doi.org/10.1016/j.biologicals.2005.01.003
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Stability and inactivation of SARS coronavirusMedical Microbiology and Immunology, 2004
- NAT screening of blood donors for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissionsTransfusion, 2004
- Risk Factors for SARS among Persons without Known Contact with SARS Patients, Beijing, ChinaEmerging Infectious Diseases, 2004
- Severe Acute Respiratory Syndrome, Beijing, 2003Emerging Infectious Diseases, 2004
- The Genome Sequence of the SARS-Associated CoronavirusScience, 2003
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeThe New England Journal of Medicine, 2003
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003
- The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionationTransfusion, 1990
- Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinationsTransfusion, 1985